A New York jury awarded $2 million to a woman in 2004. She had suffered from side effects of Rezulin. Though she did not suffered permanent liver damaged, but she needed hospitalization and took some time to recover. This was one of the trials, which were awaited desperately. This case paved way for many Rezulin lawsuits waiting in the line.

Around 8,700 Rezulin lawsuits were filed in state and federal courts across the country. Thus this trial was waited to decide the fate of the mass tort filed against Pfizer related to Rezulin side effects. It was originally manufactured by Warner-Lambert. Later Pfizer Inc. purchased Warner-Lambert and was involved with all the cases associated with the diabetic drug Rezulin.

Rezulin is an oral anti hyperglycemic drug. It contains Troglitazone as its main active ingredient. It is used to manage type II diabetes or diabetes mellitus. It is non-insulin dependant type of diabetes. Rezulin decreases insulin resistance. It makes muscles and adipose tissues more responsive to insulin. It helps to improve body respond to insulin. It controls blood sugar level by reducing sugar produced in liver. Troglitazone has hepatic gluconeogenesis properties. Troglitazone has been withdrawn from the U.S. market in 2000.

The above said lawsuit was filed by Concepcion Morgado. She started Rezulin in May 1998. She developed Jaundice and high level of liver enzymes. She was hospitalized for ten days in August 1998. She took around five months to recover fully. She did not suffer permanent liver damage, but she had suffered due to side effect of diabetic drug Rezulin.

Company had argued in the past in other cases that the liver damage caused to the patients were not due to use of Rezulin but it might have developed due to diabetes itself or other drugs used for its treatment. But in this case Pfizer’s attorney accepted that Morgado’s condition was due to use of Rezulin. But he argued that company could not be held liable for her condition, as the warning related to this side effect had been provided on the label of the drug. Thus company was not responsible in this case.

Plaintiff’s attorney argued that provided on the label of the drug was not specific, thus was not significant. The label use word rare many times, which was not adequate to warn patients about the high amount of risk involved with use of this drug.

The jury ruled in favor of plaintiff and held the defendant company Pfizer Inc. liable for her condition. Jury awarded $2 million to the plaintiff as compensation. This verdict was seen as booster for other Rezulin lawsuits. It was the seventh Rezulin case to go for a Jury. Previous cases were ruled in favor of either plaintiff or defendant.

FDA issued many safety alerts related to side effects of Rezulin. FDA finally decided to withdraw it from the market on 21st March 2000. This action was a result of safety review of Rezulin and two other similar drugs rosiglitazone (Avandia) and pioglitazone (Actos), by FDA. FDA came to a conclusion that Rezulin was not a safe drug and patients using this drug were at a continual hazard of developing severe health problems including liver or heart failure. It stated that Rezulin posed an unacceptable risk to patients.